TrialFrontiers in immunology2024

A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers.

Richard T Kenney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.